Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis

Fineline Cube Apr 7, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Deals

Luye Pharma Group Partners with Duopharma for Exclusive Marketing Rights of TCM in Malaysia

Fineline Cube Apr 7, 2023

China-based Luye Pharma Group (HKG: 2186) has signed an agreement with Malaysia’s Duopharma Marketing Sdn...

Company Deals

Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241

Fineline Cube Apr 7, 2023

US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre,...

Company Deals

Sanofi Partners with Shenzhen’s Pingshan District to Boost Innovative Vaccines in China

Fineline Cube Apr 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district...

Company Drug

Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study

Fineline Cube Apr 6, 2023

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for...

Company Drug

Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment

Fineline Cube Apr 6, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for...

Company Drug

Mabwell’s 9MW2821 ADC Shows Positive Signals in Solid Tumor Clinical Data

Fineline Cube Apr 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced preliminary clinical data for its...

Company Deals R&D

Gates Foundation and NSFC Launch Partnership to Boost Regulatory Science in Vaccine Development

Fineline Cube Apr 6, 2023

The Bill & Melinda Gates Foundation (Gates Foundation) and the National Natural Science Foundation of...

Company Drug

AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital

Fineline Cube Apr 6, 2023

AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and...

Policy / Regulatory

Provincial Budgets Highlight Top Earning Hospitals in China for 2023

Fineline Cube Apr 6, 2023

Provincial governments have revealed the budget for provincial hospitals’ expected income during 2023, offering a...

Company Drug

Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan

Fineline Cube Apr 6, 2023

Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal...

Company Deals

Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector

Fineline Cube Apr 6, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company

AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role

Fineline Cube Apr 6, 2023

Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV),...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for Two Clinical Trials

Fineline Cube Apr 6, 2023

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced two clinical trial approvals from the National...

Company Drug

Everest Medicines’ Nefecon NDA Accepted for Review by Singapore’s HSA

Fineline Cube Apr 6, 2023

China-based Everest Medicines (HKG: 1952) has announced that the Health Sciences Authority (HSA) of Singapore...

Company Drug

Hutchison China Meditech Initiates Two Phase II Studies for HMPL-453 and Orpathys

Fineline Cube Apr 6, 2023

China-based Hutchison China Meditech (HutchMed, NASDAQ: HCM, HKG: 0013) has announced that the first subjects...

Company Deals

Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda

Fineline Cube Apr 6, 2023

China-based Evopoint Biosciences has announced a collaboration agreement with US major Merck Sharp & Dohme...

Company Deals R&D

AstraZeneca and HKSTP Expand Collaboration with MoU to Support Start-Ups

Fineline Cube Apr 6, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp....

Company Drug

CStone Pharmaceuticals’ Sugemalimab Files for New Indication with NMPA for Esophageal Cancer

Fineline Cube Apr 6, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B

Fineline Cube Apr 6, 2023

Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...

Posts pagination

1 … 592 593 594 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.